Long-Term Cardiovascular Safety of Melatonin: Why Dose, Duration, and Patient Phenotype Matter

Authors:

Abstract
The long-term cardiovascular safety of melatonin remains an important area of clinical uncertainty. This editorial examines the challenges involved in evaluating cardiovascular risk associated with prolonged melatonin exposure, emphasizing the importance of dose, treatment duration, formulation, product quality, and patient characteristics. Particular attention is given to methodological limitations that complicate the interpretation of observational associations, including residual confounding, reverse causation, and exposure misclassification. The discussion also considers potential biological mechanisms while distinguishing mechanistic hypotheses from established causal relationships. A more comprehensive approach to cardiovascular safety assessment is proposed, incorporating precise exposure characterization, clinically relevant cardiovascular outcomes, and patient phenotyping. Future research should integrate these factors through appropriately designed clinical trials and observational studies to clarify the cardiovascular implications of long-term melatonin use. Until stronger evidence becomes available, clinical interpretation should acknowledge the remaining uncertainty rather than assuming either cardiovascular safety or harm.

This publication has 17 references indexed in Scilit: